These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 24849268)

  • 1. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy.
    Kimer N; Krag A; Møller S; Bendtsen F; Gluud LL
    Aliment Pharmacol Ther; 2014 Jul; 40(2):123-32. PubMed ID: 24849268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Branched-chain amino acids for people with hepatic encephalopathy.
    Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
    Cochrane Database Syst Rev; 2015 Feb; (2):CD001939. PubMed ID: 25715177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Branched-chain amino acids for people with hepatic encephalopathy.
    Gluud LL; Dam G; Les I; Marchesini G; Borre M; Aagaard NK; Vilstrup H
    Cochrane Database Syst Rev; 2017 May; 5(5):CD001939. PubMed ID: 28518283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Branched-chain amino acids for people with hepatic encephalopathy.
    Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
    Cochrane Database Syst Rev; 2015 Sep; (9):CD001939. PubMed ID: 26377410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Gluud LL; Vilstrup H; Morgan MY
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD003044. PubMed ID: 27153247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Gluud LL; Vilstrup H; Morgan MY
    Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
    Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifaximin: new therapeutic indication and future directions.
    Rivkin A; Gim S
    Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.
    Jiang Q; Jiang XH; Zheng MH; Jiang LM; Chen YP; Wang L
    Eur J Gastroenterol Hepatol; 2008 Nov; 20(11):1064-70. PubMed ID: 19047837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.
    Eltawil KM; Laryea M; Peltekian K; Molinari M
    World J Gastroenterol; 2012 Feb; 18(8):767-77. PubMed ID: 22371636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis.
    Fang G; Liu S; Liu B
    BMC Gastroenterol; 2024 Mar; 24(1):94. PubMed ID: 38439005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
    Gluud LL; Dam G; Borre M; Les I; Cordoba J; Marchesini G; Aagaard NK; Vilstrup H
    Metab Brain Dis; 2013 Jun; 28(2):221-5. PubMed ID: 23275147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis.
    Fu J; Gao Y; Shi L
    PLoS One; 2022; 17(4):e0267647. PubMed ID: 35471992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifaximin treatment in hepatic encephalopathy.
    Bass NM; Mullen KD; Sanyal A; Poordad F; Neff G; Leevy CB; Sigal S; Sheikh MY; Beavers K; Frederick T; Teperman L; Hillebrand D; Huang S; Merchant K; Shaw A; Bortey E; Forbes WP
    N Engl J Med; 2010 Mar; 362(12):1071-81. PubMed ID: 20335583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Rifaximin in the Prevention of Recurrent Episodes of Hepatic Encephalopathy: A Systematic Review and Meta-analysis.
    Elmoursi A; Abdelsattar AT; Khalil F; Shabana H; Zedan HA; El Mancy IM; Ramadan IG; Mostafa S
    Turk J Gastroenterol; 2023 Jun; 34(6):584-592. PubMed ID: 37051626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy.
    Wang Z; Chu P; Wang W
    Drug Des Devel Ther; 2019; 13():1-11. PubMed ID: 30587923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis.
    Bajaj JS; Barrett AC; Bortey E; Paterson C; Forbes WP
    Aliment Pharmacol Ther; 2015 Jan; 41(1):39-45. PubMed ID: 25339518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
    Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.